Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alector

Alector?uq=PEM9b6PF
2013 FOUNDED
PRIVATE STATUS
51-60 EMPLOYEES
Series E LATEST DEAL TYPE
$133M LATEST DEAL AMOUNT
26 INVESTORS
Description

Developer of antibody technology designed to treat neurodegenerative diseases and cancer. The company's antibody technology generates and validates antibody drugs with functional properties that engage disease altering targets and develops novel therapeutics for alzheimer disease and other neurodegenerative disorders, enabling physicians harness the immune system to fight dementia and neurodegeneration.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 151 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States

+1 (415) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Alector’s full profile, request a free trial.

Alector Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series E) 25-Jul-2018 $133M 00000 00000 Completed Startup
6. Later Stage VC (Series D) 07-Jan-2016 000.00 000.00 Completed Startup
5. Later Stage VC (Series C) 16-Sep-2015 000.00 0000 00000 Completed Startup
4. Corporate 10-Mar-2014 Completed Startup
3. Accelerator/Incubator 01-Jan-2014 Completed Startup
2. Early Stage VC (Series A) 31-Oct-2013 Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Alector Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alphabet Corporation Minority 000 0000 000000 0
Casdin Capital Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Eli Lilly Corporation Minority 000 0000 000000 0
Euclidean Capital Other Minority 000 0000 000000 0
You’re viewing 5 of 26 investors. Get the full list »

Alector Executive Team (15)

Name Title Board
Seat
Contact
Info
Arnon Rosenthal Ph.D Co-Founder, Chief Executive Officer & Board Member
Sabah Oney Ph.D Chief Business Officer
Tillman Gerngross Ph.D Chairman & Co-Founder
Calvin Yu Head, Finance
Stephanie Yonker Ph.D Vice President, Legal

5 Former Executives

You’re viewing 5 of 15 executives. Get the full list »

Alector Board Members (12)

Name Representing Role Since Contact
Info
Arnon Rosenthal Ph.D Alector Co-Founder, Chief Executive Officer & Board Member 000 0000
Carl Gordon Ph.D OrbiMed Board Member 000 0000
Christine Brennan Ph.D MRL Ventures Fund Board Member 000 0000
James Sullivan Ph.D AbbVie Ventures Board Observer 000 0000
Janis Naeve Ph.D Amgen Ventures Board Observer 000 0000
You’re viewing 5 of 12 board members. Get the full list »